Hidradenitis Suppurativa Clinical Trial
Official title:
Examining Engagement Trends Among Participants in Hidradenitis Suppurativa Clinical Trials
| NCT number | NCT06201858 |
| Other study ID # | 67172350 |
| Secondary ID | |
| Status | Not yet recruiting |
| Phase | |
| First received | |
| Last updated | |
| Start date | January 2025 |
| Est. completion date | January 2027 |
This study aims to uncover the factors driving patient decisions regarding enrollment, withdrawal, or re-engagement in hidradenitis suppurativa clinical trials. Understanding these factors will significantly improve the relevance and effectiveness of future research endeavors. Ultimately, this trial endeavors to deepen our understanding of the factors impacting hidradenitis suppurativa clinical trial participation. Enhancing participation rates could accelerate the development of innovative treatments for this debilitating condition.
| Status | Not yet recruiting |
| Enrollment | 500 |
| Est. completion date | January 2027 |
| Est. primary completion date | January 2026 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Aged = 18 years old - Diagnosis of hidradenitis suppurativa - Able to comprehend the investigational nature of the protocol and provide informed consent Exclusion Criteria: - Female patients who are currently pregnant or nursing - Inability to perform regular electronic reporting - Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. |
| Country | Name | City | State |
|---|---|---|---|
| United States | Power Life Sciences | San Francisco | California |
| Lead Sponsor | Collaborator |
|---|---|
| Power Life Sciences Inc. |
United States,
Garcovich S, Fania L, Caposiena D, Giovanardi G, Chiricozzi A, De Simone C, Tartaglia C, Ciccone D, Bianchi L, Abeni D, Peris K. Pediatric Hidradenitis Suppurativa: A Cross-Sectional Study on Clinical Features and Treatment Approaches. J Cutan Med Surg. 2022 Mar-Apr;26(2):127-134. doi: 10.1177/12034754211039993. Epub 2021 Oct 6. — View Citation
Jfri A, Nassim D, O'Brien E, Gulliver W, Nikolakis G, Zouboulis CC. Prevalence of Hidradenitis Suppurativa: A Systematic Review and Meta-regression Analysis. JAMA Dermatol. 2021 Aug 1;157(8):924-931. doi: 10.1001/jamadermatol.2021.1677. — View Citation
Saunte DML, Jemec GBE. Hidradenitis Suppurativa: Advances in Diagnosis and Treatment. JAMA. 2017 Nov 28;318(20):2019-2032. doi: 10.1001/jama.2017.16691. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number of hidradenitis suppurativa patients who decide to enroll in a clinical research | 3 months | ||
| Primary | Rate of hidradenitis suppurativa patients who remain in clinical trial to trial completion | 12 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02904902 -
Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa
|
Phase 3 | |
| Completed |
NCT03628924 -
A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
|
Phase 2 | |
| Not yet recruiting |
NCT05531747 -
Replicative Stress in Hair Follicle Stem Cells and Pathogeny of Hidradenitis Suppurativa
|
N/A | |
| Recruiting |
NCT06028230 -
A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
|
Phase 2 | |
| Completed |
NCT03275870 -
Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa
|
Phase 1/Phase 2 | |
| Completed |
NCT03248531 -
A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.
|
Phase 2 | |
| Withdrawn |
NCT04100083 -
Spironolactone for Hidradenitis Suppurativa
|
Phase 4 | |
| Completed |
NCT00329823 -
Etanercept in Hidradenitis Suppurativa
|
Phase 2 | |
| Recruiting |
NCT05710393 -
Hidradenitis - an Analysis of Genetic Traits and Linkages in Families
|
||
| Completed |
NCT04019041 -
A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa
|
Phase 2 | |
| Completed |
NCT05286567 -
A Double-blind Placebo-controlled Randomized Trial Evaluating the Efficacy and Safety of a Novel HSP90 Inhibitor (RGRN-305) in the Treatment of Moderate to Severe Hidradenitis Supppurativa.
|
Phase 1 | |
| Withdrawn |
NCT03929835 -
Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa
|
Phase 2 | |
| Terminated |
NCT04325607 -
Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa
|
N/A | |
| Terminated |
NCT03238469 -
Microwave Ablation in Mild Axillary Hidradenitis Suppurativa
|
N/A | |
| Completed |
NCT04449354 -
HidraWear AX HS Study
|
N/A | |
| Recruiting |
NCT06123429 -
Mindfulness in Hidradenitis Suppurativa
|
N/A | |
| Recruiting |
NCT05934825 -
Clinical Trial to Evaluate Safety and Efficiency of Mesenchymal Stem Cell in Patients With Hidradenitis Suppurativa
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
| Recruiting |
NCT06046729 -
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
|
Phase 2 | |
| Recruiting |
NCT04246372 -
Tofacitinib for Immune Skin Conditions in Down Syndrome
|
Phase 2 |